SNCE - Science 37 Syapse team for faster patient enrollment in cancer trials
- Science 37 ( NASDAQ: SNCE ) Syapse said they are collaborating to deploy proprietary real-world data intelligence and analytics to help identify suitable patients for oncology clinical trials, thus helping speed up the enrollment process.
- "By partnering with Syapse, we will have the ability to tap into advanced data-intelligence capabilities to make effective trial identification and recruitment a reality for patients and sponsors," said Science 37 Chief Medical Officer Jonathan Cotliar.
For further details see:
Science 37, Syapse team for faster patient enrollment in cancer trials